menu
    • menu
    [{"orgOrder":0,"company":"MorphoSys","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Guselkumab","moa":"IL-23 receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MorphoSys \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Royalty Pharma"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ Incyte Corporation","highestDevelopmentStatusID":"9","companyTruncated":"MorphoSys \/ Incyte Corporation"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Incyte Corporation","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Incyte Corporation"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"||CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved FDF","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Gantenerumab","moa":"Amyloid-beta","graph1":"Neurology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MorphoSys \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"||EZH1\/2","graph1":"Oncology","graph2":"Phase I","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Otilimab","moa":"||G-CSF receptor","graph1":"Immunology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD-38","graph1":"Nephrology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Felzartamab","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"HIBio","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Felzartamab","moa":"CD-38","graph1":"Immunology","graph2":"Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ HIBio","highestDevelopmentStatusID":"8","companyTruncated":"MorphoSys \/ HIBio"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Lenalidomide","moa":"||CD47","graph1":"Oncology","graph2":"Preclinical","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"MorphoSys \/ Pfizer Inc"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"Dexamethasone","moa":"||CD-38","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MorphoSys \/ I-Mab Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ I-Mab Biopharma"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tulmimetostat","moa":"EZH1\/2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"MOR210","moa":"||C5a receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ I-Mab Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"MorphoSys \/ I-Mab Biopharma"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MorphoSys \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Inapplicable"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MorphoSys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Pelabresib","moa":"||BET","graph1":"Oncology","graph2":"Phase III","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MorphoSys \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"MorphoSys \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"MorphoSys","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Lenalidomide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"MorphoSys","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MorphoSys \/ Xencor","highestDevelopmentStatusID":"1","companyTruncated":"MorphoSys \/ Xencor"}]

    Find Clinical Drug Pipeline Developments & Deals by MorphoSys

    Menu

    MorphoSys

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novartis Meets All Tender Offer Conditions to Acquire MorphoSys for EUR 68 per Share

                            Details : Novartis will begin to progress the integration of MorphoSys, including full access to CPI-0610 (pelabresib), a novel BET inhibitor in combination with ruxolitinib for patients with myelofibrosis.

                            Product Name : CPI-0610

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 16, 2024

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafasitamab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Incyte Corporation

                            Deal Size : $25.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Incyte Gains Exclusive Global Rights for Tafasitamab (Monjuvi®) Development

                            Details : Under the agreement, Incyte gains exclusive global rights for tafasiatamab, a humanized CD19-targeting immunotherapy marketed in the U.S. as Monjuvi.

                            Product Name : Monjuvi

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            May 02, 2024

                            Lead Product(s) : Tafasitamab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Incyte Corporation

                            Deal Size : $25.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $2,897.9 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Novartis Acquires MorphoSys AG To Strengthen Oncology Pipeline

                            Details : Novartis aims to enhance its oncology pipeline with CPI-0610 (pelabresib), a novel treatment for myelofibrosis with a favorable safety profile when combined with ruxolitinib.

                            Product Name : CPI-0610

                            Product Type : Other Small Molecule

                            Upfront Cash : $2,897.9 million

                            May 02, 2024

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $2,897.9 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tulmimetostat,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

                            Details : CPI-0209 (tulmimetostat) is an investigational compound designed to exert anti-tumor activity by inhibiting the EZH2 and EZH1, which is investigated for the treatment of endometrial cancer.

                            Product Name : CPI-0209

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 09, 2023

                            Lead Product(s) : Tulmimetostat,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement i...

                            Details : CPI-0610 (pelabresib monohydrate) is an investigational BET inhibitor. It is being developed in combination with the JAK inhibitor ruxolitinib for the treatment of myelofibrosis.

                            Product Name : CPI-0610

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 20, 2023

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tafasitamab,Lenalidomide

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology A...

                            Details : Monjuvi (tafasitamab-cxix), is a humanized Fc-modified CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab.

                            Product Name : Monjuvi

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 05, 2022

                            Lead Product(s) : Tafasitamab,Lenalidomide

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gantenerumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alz...

                            Details : RO4909832 (gantenerumab) is fully-human mAB, studies did not meet their primary endpoint of slowing clinical decline. The level of beta-amyloid removal, the protein that builds up to make plaques in the brains of people with Alzheimer's disease.

                            Product Name : RO4909832

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            November 14, 2022

                            Lead Product(s) : Gantenerumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otilimab,Methotrexate,Sulfasalazine

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to S...

                            Details : GSK3196165 (otilimab) is an investigational human monoclonal antibody directed against GM-CSF (granulocyte-macrophage colony-stimulating factor) that is developed by GSK for the treatment of rheumatoid arthritis.

                            Product Name : GSK3196165

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 27, 2022

                            Lead Product(s) : Otilimab,Methotrexate,Sulfasalazine

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tulmimetostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potenti...

                            Details : CPI-0209 (tulmimetostat) is an oral, investigational next-generation selective dual inhibitor of EZH2 and EZH1 designed to improve on first generation EZH2 inhibitors via increased potency, longer residence time on target and a longer half-life.

                            Product Name : CPI-0209

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 27, 2022

                            Lead Product(s) : Tulmimetostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            MorphoSys

                            Germany arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib i...

                            Details : Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain proteins to decrease the expression of abnormally expressed genes in cancer.

                            Product Name : CPI-0610

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 06, 2022

                            Lead Product(s) : Pelabresib,Ruxolitinib Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth